Author:
Safarpour Yasaman,Mousavi Tahereh,Jabbari Bahman
Publisher
Springer Science and Business Media LLC
Reference88 articles.
1. Dilokthornsakul P, Valuck RJ, Nair KV, Corboy JR, Allen RR, Campbell JD. Multiple sclerosis prevalence in the United States commercially insured population. Multiple sclerosis prevalence in the United States commercially insured population. Neurology. 2016;86:1014–21.
2. Zwibel HL, Smrtka J. Improving quality of life in multiple sclerosis: an unmet need. Am J Manag Care. 2011;17(Suppl 5 Improving):S139–45.
3. Adelman G, Rane SG, Villa KF. The cost burden of multiple sclerosis in the United States: a systematic review of the literature. J Med Econ. 2013;16:639–47.
4. Botulinum Toxin-Therapeutic clinical practice and science. Jankovic, Albenese, Atassi, Dolly, Hallett, Mayer (Editors). 2009 Sanders-Elsevier Publisher, Philadelphia.
5. Montecucco C, Rasotto MB. On botulinum neurotoxin variability. MBio. 2015;6:e02131–14.
Cited by
21 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献